Funding for this research was provided by:
Flemish Innovation and Entrepreneurship (Baekeland grant no. 140249)
Janssen Pharmaceutica (Research jointly funded with VLAIO under same grant no. 140249)
Received: 1 November 2017
Accepted: 12 June 2019
First Online: 19 June 2019
Ethics approval and consent to participate
: The human data analyzed in this study originated from studies that previously received ethics approval. Participant consent is not necessary in this study as it involved the use of previously-published de-identified data. On 21 November 2017 the Ghent University Medical Ethics Commission concluded that the ethical rules were observed and according to the normal submission of files the committee has no ethical objections concerning this study.
: Not applicable.
: SK and BH are employees of Janssen Pharmaceutica, an operating company of Johnson & Johnson and also hold stock and options in Johnson & Johnson. This work was carried out as part of a PhD program jointly funded by the Flemish government (Flemish Innovation and Entrepreneurship, VLAIO) and Janssen Pharmaceutica as a Baekeland mandate grant (no. 140249) of SD. SD received travel funding through the Baekeland mandate grant. JD worked as a consultant for Janssen Pharmaceutica. DDS declares no actual or potential competing financial interests.